Syngene trades weak after nearly 6% equity changes hands via block deals


Shares of traded 1 per cent lower at Rs 573.95 at 10:14 AM after nearly 6 per cent of the company’s equity changed hands via block deals on the BSE on Tuesday.

At 09:15 am; around 22.68 million equity shares representing 5.65 per cent of the total equity of Syngene changed hands on the BSE at price of Rs 585.80, the exchange data shows. The names of the buyers and sellers are not ascertained immediately.

The stock opened 3 per cent lower at Rs 561.75 against its previous close of Rs 578.75 on the BSE. It hit a high of Rs 599 and a low of Rs 559 in intra-day trades so far, the exchange data shows.

As on June 30, 2022, of the total promoters’ holding of 70.29 per cent, Biocon held 69.99 per cent stake in Syngene, the shareholding pattern data shows.

In the past one week, Syngene has underperformed the market by falling 4 per cent, as compared to 0.30 decline in the Sensex. In the past one year, the stock has declined 8 per cent, as against 1.8 per cent gain in the benchmark index. It had hit a 52-week low of Rs 508 on February 22, 2022.

Meanwhile, Biocon had hit a 52-week low of Rs 290.75 on Monday. In the past one week, the stock has slipped 6 per cent, while in the past one year it has fallen 19 per cent.

Syngene is engaged in a single operating segment of providing contract research and manufacturing services. The company in its FY22 annual report said that the fundamentals of the Company’s Small Molecule Contract Development and Manufacturing Organization (CDMO) Services are robust with an integrated platform for development and commercial manufacturing.

The company’s focused on new chemical entities (NCEs) and molecule flow through from Discovery Services and from early stage to late-stage clinical trials is expected to drive capacity utilization. The commercial manufacturing facility is expected to ramp up utilization post USFDA approval expected in H2FY24, Syngene said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor


Source link

Comments are closed.